US Bladder Cancer Statistics - BCAM 2021 | Cxbladder

Bladder cancer is the 10th most common cancer globally, the 4th most common cancer among US men, and the 6th most common in the US overall. Bladder Cancer Awareness Month is a time for those affected by the disease to stand together in an effort to increase awareness of the disease and fundraise for bladder cancer research, treatment and care. It’s also a time for patients to share their stories, educating and inspiring others affected by the disease. For those that have lost loved ones to bladder cancer, May is a time to remember and to honour the memory of those that have passed.
In this video we share some key US bladder cancer statistics linked to likelihood, recurrence, and survival. To learn more, please visit: www.cxbladder.....
If you're concerned about bladder cancer, ask your doctor about Cxbladder
Cxbladder is a non-invasive genomic urine test that quickly and accurately detects or rules out bladder cancer in hematuria patients and those being monitored for bladder cancer recurrence. The test combines clinical risk factor markers with genetic information, measuring five biomarker genes to detect the presence or absence of bladder cancer.
Cxbladder gives you certainty, resolving diagnostic ambiguity and improving overall detection accuracy. Most patients experiencing hematuria or who are being monitored for bladder cancer recurrence do not have cancer. Cxbladder enables the accurate rule out of patients who do not have bladder cancer, reducing the need for further invasive tests.
With performance proven in 12 peer-reviewed studies, Cxbladder is trusted by over 1,800 US urologists in over 40,000 patients. The test is covered by Medicare and comes with the option of in-home sampling.
Learn more bladder cancer and Cxbladder at: www.cxbladder.com